MedTrace Logo

Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

NCT00665834 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-03-29

No results posted yet for this study

Summary

This is a 3-month, randomized, parallel-group study with 2 periods, comparing the efficacy and the safety of rosuvastatin 20 mg versus atorvastatin 80 mg in patients with an acute coronary syndrome (ACS).

Conditions

Interventions

DRUG

rosuvastatin

rosuvastatin 20 mg from day 0 to (maximum) day 6

DRUG

placebo

placebo 20 mg from day 0 to (maximum) day 6

DRUG

rosuvastatin

rosuvastatin 20 mg from discharge until the end of the study

DRUG

atorvastatin

atorvastatin 80 mg from discharge until the end of the study

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Queen's University

    lead OTHER

Principal Investigators

  • Stephen A LaHaye, MD · Queen's University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2007-09-30
Completion
2007-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00665834 on ClinicalTrials.gov